Abstract:Background High-level expression of NAD(P)H: quinoneoxidoreductase 1 (NQO1) has been correlated with many types of human cancers, suggesting that NQO1 plays important roles in tumor occurrence and progression. This study attempted to explore the role of NQO1 in tumor progression and prognostic evaluation of non-small cell lung cancer (NSCLC). Methods Total 164 tissue samples, including 150 NSCLC paired with the adjacent non-tumor tissues and 14 normal lung tissues, were picked-up for immunohistochemical (IHC) staining of the NQO1 protein, and immunofluorescence (IF) staining was also performed to detect the subcellular localization of the NQO1 protein in A549 human lung cancer cells. The correlation between NQO1 expression and clinicopathological characteristics were evaluated by Chi-square test and Fisher’s exact tests. The disease-free survival (DFS) and overall survival (OS) rates of NSCLC patients were calculated by the Kaplan-Meier method, and univariate and multivariate analyses were performed using the Cox proportional hazards regression model. Results The NQO1 protein showed a mainly cytoplasmic staining pattern in lung cancer cells, including adenocarcinoma and squamous cell carcinoma (SCC). Both positive rate and strongly positive rate of NQO1 protein expression were significantly higher in NSCLC (59.3% and 28.0%) than that in adjacent non tumor (8.0% and 1.3%) and normal lung tissues (0%). The positive rate of NQO1 was related with clinical stage and lymph node metastasis, and the strongly positive rate of NQO1 protein was significantly correlated with tumor size, poor differentiation, advanced clinical stage and lymph node metastasis in NSCLC. Additionally, survival analyses showed that the patients with NQO1 positive expression had lower OS rates compared with those with NQO1 negative expression in the groups of T1-2, T3-4, without LN metastasis and stage I-II of NSCLC, respectively; however, in the groups of patients with LN metastasis or III-IV stages, OS rate was not correlated with NQO1 expression status. Moreover, multivariate analysis suggested that NQO1 emerged as a significant independent prognostic factor along with tumor size, differentiation, lymph node metastasis and clinical stage in patients with NSCLC. Conclusions NQO1 is upregulated in NSCLC, and it may be a useful poor prognostic biomarker and a potential therapeutic target for patients with NSCLC.

Clinical Implications of High NQO1 Expression in Breast Cancers

Quinone Oxidoreductase 1 is Overexpressed in Gastric Cancer and Associated with Outcome of Adjuvant Chemotherapy and Survival.

NQO1 protein expression predicts poor prognosis of non-small cell lung cancers

High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma

Pan-cancer and single-cell analysis reveal the prognostic value and immune response of NQO1

Clinicopathological Implications of NQO1 Overexpression in the Prognosis of Pancreatic Adenocarcinoma

Prognostic Implication of NQO1 Overexpression in Hepatocellular Carcinoma.

Clinicopathological and prognostic significance of NQO1 protein expression in patients with colorectal carcinoma

Nad(P)H:Quinone Oxidoreductase-1 Overexpression Predicts Poor Prognosis in Small Cell Lung Cancer

NQO1 Overexpression is Associated with Poor Prognosis in Squamous Cell Carcinoma of the Uterine Cervix

Prognostic significance of NAD (P) H-quinone oxidoreductase 1 overex-pression in ovarian mucinous cystadenocarcinoma

Significance of Nqo1 Overexpression for Prognostic Evaluation of Gastric Adenocarcinoma

Prognostic significance of NADPH quinine oxidoreductase 1 overexpression in head and neck squamous cell carcinoma

Significant Association of PKM2 and NQO1 Proteins with Poor Prognosis in Breast Cancer.

The NQO1/PKLR Axis Promotes Lymph Node Metastasis and Breast Cancer Progression by Modulating Glycolytic Reprogramming

NAD(P)H:Quinone Oxidoreductase 1 (NQO1) as a Therapeutic and Diagnostic Target in Cancer.

Human NQO1 as a Selective Target for Anticancer Therapeutics and Tumor Imaging

NAD(P)H: Quinone Oxidoreductase 1 Overexpression in Hepatocellular Carcinoma Potentiates Apoptosis Evasion Through Regulating Stabilization of X-linked Inhibitor of Apoptosis Protein.

Clinical Implication of Keap1 and Phosphorylated Nrf2 Expression in Hepatocellular Carcinoma.

NQO1 promotes an aggressive phenotype in hepatocellular carcinoma <i>via</i> amplifying ERK‐NRF2 signaling

Tumor Suppressive Function of NQO1 in Cutaneous Squamous Cell Carcinoma (SCC) Cells